Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.
Bono
P
P
Elfving
H
H
Utriainen
T
T
Osterlund
P
P
Saarto
T
T
Alanko
T
T
Joensuu
H
H
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001794:Blood Pressure / Q000187:drug effects; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D016001:Confidence Intervals; D018450:Disease Progression; D004334:Drug Administration Schedule; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007680:Kidney Neoplasms / Q000473:pathology*; D008875:Middle Aged; D011507:Proteinuria / Q000139:chemically induced; D016019:Survival Analysis; D013997:Time Factors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab